Literature DB >> 10553942

Tissue type plasminogen activator amplifies hemoglobin-induced neurotoxicity in rat neuronal cultures.

X Wang1, M Asahi, E H Lo.   

Abstract

Tissue type plasminogen activator (tPA) is clinically used as a form of thrombolytic therapy for acute ischemic stroke. However, recent data suggest that there may be negative effects associated with tPA. Experimental studies show that tPA amplifies excitotoxic neuronal damage and clinical trials show that some stroke patients suffer from hemorrhage after tPA therapy. Since hemoglobin is the major component of blood, we tested the hypothesis that tPA can amplify hemoglobin-induced neurotoxicity. PC12 cells and primary cortical rat neurons were exposed to either hemoglobin alone or hemoglobin plus tPA. Hemoglobin induced dose-dependent cytotoxicity. The addition of tPA significantly increased hemoglobin-induced cell death. These results raise the important possibility that tPA may worsen outcomes after hemorrhage.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10553942     DOI: 10.1016/s0304-3940(99)00682-5

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  15 in total

1.  Tissue Plasminogen Activator: Side Effects and Signaling.

Authors:  Ling Lin; Kebin Hu
Journal:  J Drug Des Res       Date:  2014-09-25

2.  NAD replenishment with nicotinamide mononucleotide protects blood-brain barrier integrity and attenuates delayed tissue plasminogen activator-induced haemorrhagic transformation after cerebral ischaemia.

Authors:  Chun-Chun Wei; Yuan-Yuan Kong; Xia Hua; Guo-Qiang Li; Si-Li Zheng; Ming-He Cheng; Pei Wang; Chao-Yu Miao
Journal:  Br J Pharmacol       Date:  2017-09-06       Impact factor: 8.739

3.  Hemin-induced apoptosis in PC12 and neuroblastoma cells: implications for local neuronal death associated with intracerebral hemorrhage.

Authors:  Yossef S. Levy; Jonathan Y. Streifler; Hanna Panet; Eldad Melamed; Daniel Offen
Journal:  Neurotox Res       Date:  2002 Nov-Dec       Impact factor: 3.911

Review 4.  New insights into targeting mitochondria in ischemic injury.

Authors:  Jingjing Jia; Haiqiang Jin; Ding Nan; Weiwei Yu; Yining Huang
Journal:  Apoptosis       Date:  2021-03-09       Impact factor: 4.677

Review 5.  Can the time window for administration of thrombolytics in stroke be increased?

Authors:  Geoffrey A Donnan; David W Howells; Romesh Markus; Danilo Toni; Stephen M Davis
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 6.  Tissue-type plasminogen activator as a therapeutic target in stroke.

Authors:  Iordanis Gravanis; Stella E Tsirka
Journal:  Expert Opin Ther Targets       Date:  2008-02       Impact factor: 6.902

7.  G-CSF, rt-PA and combination therapy after experimental thromboembolic stroke.

Authors:  Rainer Kollmar; Nils Henninger; Christian Urbanek; Stefan Schwab
Journal:  Exp Transl Stroke Med       Date:  2010-04-14

8.  The cytotoxic effect of bromoenol lactone, a calcium-independent phospholipase A2 inhibitor, on rat cortical neurons in culture.

Authors:  Shiro Kurusu; Kohtaro Matsui; Toshimichi Watanabe; Toshinobu Tsunou; Mitsumori Kawaminami
Journal:  Cell Mol Neurobiol       Date:  2008-06-05       Impact factor: 5.046

Review 9.  Novel actions of tissue-type plasminogen activator in chronic kidney disease.

Authors:  Kebin Hu; Wendy M Mars; Youhua Liu
Journal:  Front Biosci       Date:  2008-05-01

10.  Annexin A2 combined with low-dose tPA improves thrombolytic therapy in a rat model of focal embolic stroke.

Authors:  Haihao Zhu; Xiang Fan; Zhanyang Yu; Jianxiang Liu; Yoshihiro Murata; Jie Lu; Song Zhao; Katherine A Hajjar; Eng H Lo; Xiaoying Wang
Journal:  J Cereb Blood Flow Metab       Date:  2010-01-13       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.